word count: 74 23 Text word count: 1505 Middle East respiratory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 25 4 (DPP4) as an entry receptor. Mouse DPP4 (mDPP4) does not support MERS-CoV entry; 26 however, changes at positions 288 and 330 can confer permissivity. Position 330 changes 27 the charge and glycosylation state of mDPP4. We show that glycosylation is a major factor 28 impacting DPP4 receptor function. These results provide insight into DPP4 species-specific 29 differences impacting MERS-CoV host range and may inform MERS-CoV mouse model 30 development. 31 Coronaviruses are a diverse family of single-stranded, positive-sense RNA viruses that 32 have frequently undergone host range expansion events. While coronaviruses have expanded 33 their host range into humans multiple times over the course of their evolutionary history, two 34 recent events have resulted in the emergence of highly pathogenic epidemic strains. First, severe 35 acute respiratory syndrome coronavirus (SARS-CoV) emerged into the human population in 36 2003 and infected over 8,000 people before finally being contained by aggressive public health 37 intervention strategies. More recently in 2012, Middle East respiratory syndrome coronavirus 38 (MERS-CoV) emerged from its zoonotic host species into humans, resulting in severe disease 39 and a 38% mortality rate. MERS-CoV likely originated from a bat reservoir species, as 40 evidenced by the identification of closely related MERS-CoV-like viruses in bats (1, 2), although 41 current hypotheses suggest that a camel intermediate host also played an important role in the 42 host range expansion event. 43 The functional receptor for MERS-CoV was recently identified as dipeptidyl peptidase 4 44 (DPP4) (3). Interestingly, while MERS-CoV can utilize human, bat, and camel DPP4 (data not 45 shown), traditional small animal models are non-permissive, including mice (4, 5), ferrets (6), 46 and hamsters (7). The relevance of MERS-CoV as an emerging pathogen and the importance of 47 126 complicating the generation of a mouse-adapted strain. Therefore, it may be necessary to 127 partially or fully humanize mDPP4 to achieve in vivo MERS-CoV replication. Additionally, the 128 finding that changes in both blades of mDPP4 is crucial for mediating permissivity to MERS-129 CoV (Fig. 3A) has two major implications. First, it may help inform future studies in other non-130 permissive hosts, particularly since single amino acid changes have not resulted in successful 131 infections (e.g ferrets (data not shown)). Second, it suggests that circulating MERS-like 132 coronaviruses cannot expand their host range into mice and possibly other rodent species with 133 just one change. Rather, extensive remodeling of the MERS-CoV RBD is likely required for it to 134 successfully utilize non-permissive DPP4 orthologs as receptors, especially if glycosylation acts 135
small animal models for studying pathogenesis and for developing vaccines and therapeutics led 48 us to identify the determinants of interactions between the MERS-CoV receptor binding domain 49 (RBD) and mouse DPP4 (mDPP4) . Interactions between DPP4 and the MERS-CoV RBD are 50 primarily restricted to blades IV and V of the DPP4 N-terminal β-propeller domain (8, 9) . 51 Recently, we found that two key residues in mDPP4 (A288L and T330R) could permit infection 52 by MERS-CoV when mutated to the human DPP4 (hDPP4) amino acids (4). These residues lie 53 within blades IV and V of the β-propeller domain (see 8, 9) . The importance of A288L can be 54 understood by recognizing that there is a strong hydrophobic region in the MERS-CoV RBD that 55 engages the equivalent hDPP4 residue (L294) (9). In fact, all permissive DPP4 orthologs have a 56 leucine residue at this site (i.e. bat, camel, human, marmoset). This interaction, however, is 57 altered in mDPP4, potentially making this hydrophobic region less amenable to interacting with 58 the MERS-CoV RBD.
59
On blade IV, the T330R substitution in mDPP4 regulates two potentially critical virus-60 host cell receptor interaction events. First, the 330 arginine provides a highly conserved charge 61 that is present in all known permissive hosts, but missing from all known non-permissive hosts 62 ( Fig. 1A) . In hDPP4, the interaction between this residue (R336 relative to hDPP4 numbering) 63 and the MERS-CoV RBD Y499 has been previously noted as a key interaction (8, 9) . The 64 absence of this interaction could be a primary factor behind the lack of permissivity of mDPP4, 65 as well as other non-permissive DPP4 orthologs. Second, the T330R mutation knocks out an 66 NXT glycosylation motif in mDPP4. Western Blot analysis is consistent with the loss of 67 glycosylation at this site, as evidenced by a ~2.5 kDa downward shift in the mDPP4 T330R 68 mutant ( Fig. 1B ). Considering these two potentially important effects, we hypothesized that 69 either the introduction of the conserved charge or the removal of glycosylation was crucial for 70 regulating mDPP4 permissivity to MERS-CoV infection.
71
To test the impact of glycosylation versus charge on the ability of mDPP4 to support 72 infection by MERS-CoV, we generated a panel of DPP4 mutants (Fig. 1C, 1D) 
79
A set of hDPP4 mutants were generated and assayed for permissivity to MERS-CoV 80 infection in order to first assess the importance of glycosylation versus charge in the human 81 context. We generated two mutants: one that included a glycosylation site and one that removed 82 the charge. First, we swapped the three residues of the NLT mDPP4 putative glycosylation site 83 with residues 334 to 336 of hDPP4 (hDPP4 + gly). This addition shows a severe reduction in 84 infection ( Fig. 2A, 2B) , with an upward shift in the Western Blot band consistent with successful 85 introduction of the glycosylation site ( Fig. 2C ). However, this mutation impacts both the 86 glycosylation site and the charged 336 residue (aligning to residue 330 in mDPP4, Fig. 1A ).
87
Therefore, our second mutant introduces the R336T mutation by itself, which removes the 88 positive charge without introducing glycosylation. While we do observe a decrease in infection, 89 it is not comparable in magnitude to the decrease seen when glycosylation is included ( Fig. 2A,   90 2B), suggesting that the presence of a positively charged residue at position 336 is not essential 91 for hDPP4-mediated MERS-CoV infection. Additionally, the presence of glycosylation does not impact the ability of hDPP4 + gly to be expressed on the cell surface (Fig. 4) . These results show 93 that glycosylation can act to inhibit infection by MERS-CoV and that the positive charge is not a 94 crucial interaction in the context of hDPP4.
95
In order to directly assess the relative contribution of charge versus glycosylation in the 96 context of mDPP4, we evaluated whether the presence of glycosylation or charge at the 330 site 97 regulates mDPP4 receptor activity. For these studies, mutations were evaluated singly and in the 98 presence of the secondary mutation (A288L), which is essential for high levels of MERS-CoV 99 receptor activity. Importantly, introduction of the charged residue at 330 simultaneously destroys 100 the glycosylation site, preventing us from testing whether the presence of the charged residue at 101 330 can enhance mDPP4 receptor activity in the presence of a glycosylation site. However, it is 102 possible to remove the glycosylation site without introducing a charged residue with the 103 mutation N328A, which disrupts the N of the NXT motif (Fig. 1A, 1D ). When we assessed the 104 N328A mutant in the context of the A288L background we observed high levels of infection 105 (Fig. 3A) that are not statistically different from mDPP4 A288L, T330R (Fig. 3B ). Both 106 glycosylation knockout mutants have levels that are statistically greater than mDPP4 but 107 statistically less than hDPP4 ( Fig 3B) . All mutants containing the T330R or N328A mutation 108 show a ~2.5 kDa downward shift in the Western Blot, consistent with the loss of glycosylation 109 (Fig. 3C ). Importantly, surface staining for mDPP4 and hDPP4 signifies that all derivatives of 110 the DPP4 receptors are expressed at the cell surface and available to interact with the MERS-
111
CoV RBD (Fig. 4) . Together, these results indicate that removal of the glycosylation site, rather 112 than addition of the charged residue at position 330, is responsible for regulating the ability of 113 MERS-CoV to utilize mDPP4 as a functional receptor. The secondary mutation, A288L, also 114 plays an important role in MERS-CoV permissivity due to the fact that high levels of infection 115 are only seen when the glycosylation mutants are combined with the A288L substitution (Fig   116   3A, 3B) . Together, this suggests that while glycosylation is an important barrier, its removal is 117 not sufficient to permit infection in the absence of the A to L modification at position 288.
118
The importance of glycosylation in the interactions between coronaviruses and host-cell 119 receptors has previously been recognized. For example, the introduction of a glycosylation site 120 into human aminopeptidase N (APN) prevents human coronavirus 229E from utilizing it as a 121 receptor (12). For MERS-CoV, it is possible that glycosylation can act as a broader determinant 122 of DPP4-mediated host range, since other non-permissive hosts (i.e. ferrets, hamsters) also have 123 a non-conserved glycosylation site in the region of DPP4 that interacts with the MERS-RBD 124 (Fig. 1A) . In the context of a small animal model, the presence of the glycosylation site at 330
